new
   The place of Vandetanib in the treatment of lesions
500
Jun 23, 2025

Vandetanib is a targeted drug for the treatment of medullary thyroid lesions (MTC), especially in patients with unresectable locally advanced or metastatic medullary thyroid lesions. It has become an important drug in the treatment of medullary thyroid lesions by inhibiting a variety of tyrosine kinases and blocking the growth and spread of diseased cells.

The place of Vandetanib in the treatment of lesions

Vandetanib plays an important role in the treatment of medullary thyroid lesions (MTC), especially for patients with unresectable locally advanced or metastatic medullary thyroid lesions. It significantly prolongs the progression-free survival of patients by inhibiting a variety of tyrosine kinases and blocking the growth and spread of diseased cells.

Mechanism of action of Vandetanib

Vandetanib blocks the growth and spread of diseased cells by inhibiting a variety of tyrosine kinases, including EGFR, VEGFR, and RET. This multi-target inhibition effect makes it effective in the treatment of medullary thyroid lesions, helping patients control disease progression.

Indications for Vandetanib

Vandetanib is indicated for patients with unresectable locally advanced or metastatic medullary thyroid lesions. It helps patients prolong progression-free survival and improve quality of life by inhibiting the growth and spread of diseased cells.

Vandetanib plays a significant role in the treatment of medullary thyroid lesions, and its therapeutic effect has been widely recognized. Next, we will detail the therapeutic effects of Vandetanib.

Therapeutic effects of Vandetanib

Vandetanib has shown significant therapeutic efficacy in the treatment of medullary thyroid lesions, particularly in patients with unresectable locally advanced or metastatic medullary thyroid lesions. It significantly prolongs progression-free survival by inhibiting multiple tyrosine kinases.

Prolongs progression-free survival

By inhibiting a variety of tyrosine kinases, Vandetanib blocks the growth and spread of diseased cells, significantly prolonging the progression-free survival of patients with medullary thyroid lesions. Clinical trial data showed that progression-free survival was significantly better in the Vandetanib treatment group than in the control group.

Improve quality of life

Vandetanib not only prolonged progression-free survival, but also significantly improved patients' quality of life. The patient's symptoms were effectively controlled during the medication, and the quality of life was significantly improved.

The therapeutic effect of Vandetanib is significant, but patients should be aware of its possible side effects and related management measures when using it. Next, we will introduce the post-use review program of Vandetanib.

Vandetanib post-use review items

The use of Vandetanib needs to be reviewed regularly, and patients should regularly monitor ECG, liver function, and blood levels during the drug period to prevent possible serious adverse reactions.

Monitor the ECG regularly

Vandetanib may cause QT interval prolongation, and patients should have their ECG monitored regularly during treatment. If the QT interval is prolonged, your doctor may adjust the dose or stop taking the medication until the ECG returns to normal.

Monitor liver function regularly

Vandetanib may cause hepatotoxicity, and patients should have regular monitoring of liver function during use. The doctor will adjust the dose of the drug or stop the drug according to the patient's liver function indicators.

Vandetanib is a prescription drug, and patients should strictly follow the doctor's instructions when using it and have regular re-examinations to prevent possible serious adverse reactions.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Vandetanib(Caprelsa)
Symptomatic or progressive medullary thyroid carcinoma, unresectable locally advanced or metastatic disease.
RELATED ARTICLES
Vandetanib therapeutic effect

Vandetanib was approved by the U.S. Food and Drug Administration in 2011 for the treatment of unresectable locally...

Monday, June 23rd, 2025, 17:54
What is the efficacy and effect of Caprelsa?

Vandetanib(Caprelsa) is a targeted drug used to treat unresectable locally advanced or metastatic medullary thyroid...

Monday, June 23rd, 2025, 17:47
Best time to take Vandetanib

Vandetanib is a targeted drug used to treat unresectable locally advanced or metastatic medullary thyroid...

Monday, June 23rd, 2025, 17:39
Indications for Vandetanib

Vandetanib is an orally targeted drug for specific thyroid disorders indicated for the treatment of...

Monday, June 23rd, 2025, 17:30
RELATED MEDICATIONS
Vandetanib
Symptomatic or progressive medullary thyroid carcinoma, unresectable locally...
TOP
1
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved